Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib QT interval study in healthy subjects
NCT02752919Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of galunisertib in hepatocellular carcinoma (HCC), pancreatic cancer (PC) and glioblastoma (GBM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Fridericia-corrected QT Interval. Started Apr 2016; status: completed.
02
Drugs
galunisertib
03
Conditions
hepatocellular carcinoma (HCC)pancreatic cancer (PC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02752919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752919.